We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Leukocyte Ratio Investigated for Familial Mediterranean Fever Patients

By LabMedica International staff writers
Posted on 28 Apr 2014
Print article
Image: Stained leukocytes in a peripheral blood smear (Photo courtesy of Dr. Kristine Krafts, MD).
Image: Stained leukocytes in a peripheral blood smear (Photo courtesy of Dr. Kristine Krafts, MD).
Blood neutrophil-to-lymphocyte (N/L) ratio is a simple marker of inflammation that can be easily obtained from the differential leucocyte count and has been used to determine disease activity and diagnosis in patients with ulcerative colitis (UC) and acute appendicitis.

Familial Mediterranean Fever (FMF) is a recurrent, autosomal recessive autoinflammatory disease characterized with fever and serositis, which is accompanied by pain in the abdominal area, chest, and joints and the disease, is common among Mediterranean communities including Turks, Armenians, Jews, and Arabs.

Scientists at the Bozok University Medical School (Yozgat, Turkey) enrolled 115 patients and controls in the study. The cases in the study were categorized as FMF with attack, FMF with attack-free period, and controls. There were 79 patients with FMF and 36 control subjects. There were 29 females and 50 males in the FMF group and 12 females and 24 males in the control group. The data collected included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total white blood cell count (WBC), neutrophil counts, lymphocyte counts, and number of platelets.

The median disease duration in FMF patients was 10 years and age and sex were similar in the FMF and control groups. The ESR was significantly higher in FMF patients during the attack phase. The CRP increased during attack but this was not statistically significant and WBC counts did not differ among groups. The mean N/L ratios of the controls was 1.63 (range: 1.41 to 2.33), for FMF patients who were attack- free the ratio was 1.83 (range 1.21 to 2.23), and for FMF patients during attack it was 2.95 (range: 1.91 to 3.46). The serum N/L ratios of FMF patients during attack were significantly higher than those of attack-free FMF patients and controls. While the serum neutrophil count increased in FMF patients during attack, in attack-free FMF patients and controls, the serum lymphocyte count did not differ.

The authors concluded that the N/L ratio, an indicator of the overall inflammatory status of the body, is higher in active FMF patients than in FMF patients in remission and healthy controls. A cut-off ratio value of 2.63 can be used to identify patients with active FMF. N/L ratio is not related with disease duration and inflammatory markers such as CRP and ESR in FMF patients. It is an inexpensive and readily available measure that could in combination with other markers help identify patients with active disease. The study was published on March 28, 2014, in the Journal of Clinical Laboratory Analysis.

Related Links:

Bozok University Medical School 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.